| This article has been cited by |
| 1 | Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs | |
| Vibeke Strand,Kurt de Vlam,Jose A Covarrubias-Cobos,Philip J Mease,Dafna D Gladman,Daniela Graham,Cunshan Wang,Joseph C Cappelleri,Thijs Hendrikx,Ming-Ann Hsu |
| RMD Open.2019;5(1)e000806 |
| [DOI] |
|
| 2 | Validation of the cognitive stimulation therapy (CST) program for people with dementia in Portugal | |
| G. Alvares-Pereira,M. V. Silva-Nunes,A. Spector |
| Aging & Mental Health.2021;25(6)1019 |
| [DOI] |
|
| 3 | Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond | |
| Vibeke Strand,Kurt de Vlam,Jose A Covarrubias-Cobos,Philip J Mease,Dafna D Gladman,Linda Chen,Elizabeth Kudlacz,Joseph Wu,Joseph C Cappelleri,Thijs Hendrikx,Ming-Ann Hsu |
| RMD Open.2019;5(1)e000808 |
| [DOI] |
|
| 4 | Novel Mineral–Vitamin Treatment for Reduction in Cigarette Smoking: A Fully Blinded Randomized Placebo-Controlled Trial | |
| Phillipa K Reihana,Neville M Blampied,Julia J Rucklidge |
| Nicotine & Tobacco Research.2019;21(11)1496 |
| [DOI] |
|
| 5 | Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis | |
| T. V. Korotaeva,E. Yu. Loginova |
| Modern Rheumatology Journal.2019;13(2)112 |
| [DOI] |
|
